Article Type
Changed
Tue, 11/29/2022 - 23:40

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Publications
Topics
Sections

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Gastric Cancer, December 2022
Gate On Date
Wed, 06/22/2022 - 12:15
Un-Gate On Date
Wed, 06/22/2022 - 12:15
Use ProPublica
CFC Schedule Remove Status
Wed, 06/22/2022 - 12:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article